Latest & Greatest

Latest & Greatest

Recent developments in the field of hematology/oncology, including drug approvals, policy updates, and clinical trial results

First Biosimilar for Anemia Treatment Approved by FDA

Epoetin alfa-epbx, a biosimilar to epoetin alfa, was approved for the treatment of anemia caused by chronic kidney disease, chemotherapy, or use of zidovudine...

Trump Administration Reveals Plans to Lower Drug Prices

In May, President Donald Trump and members of his administration outlined plans to lower prescription drug prices: First, the president unveiled initiatives to remove...

FDA Cracks Down on Unapproved Stem-Cell Clinics

The U.S. Food and Drug Administration (FDA) filed complaints in May seeking permanent injunctions against two stem cell clinics, U.S. Stem Cell Clinic of...

Andexanet Becomes First FDA-Approved Antidote for Factor Xa Inhibitors

The U.S. Food and Drug Administration (FDA) granted approval to andexanet alfa, also known as coagulation factor Xa (recombinant), inactivated-zhzo, for the reversal of...

CAR T-Cell Therapy Gets New Indication and New Price

The U.S. Food and Drug Administration (FDA) has expanded the approval of the chimeric antigen receptor (CAR) T-cell therapy tisagenlecleucel to include the treatment...

CVS Unveils Tool to Help Identify Cheaper Treatment Options

CVS Health introduced the Rx Savings Finder: A system that can check for less expensive medications, higher quantities at lower costs, and drug discounts...

FDA Issues Guidance on Next-Generation Sequencing

The U.S. Food and Drug Administration (FDA) finalized two guidance documents on recommendations for designing, developing, and validating tests that use next-generation sequencing (NGS)...

NIH Program Completes Genomic Analysis of 33 Cancer Types

Researchers announced the completion of the PanCancer Atlas, a National Institutes of Health (NIH)–funded, detailed genomic analysis of molecular and clinical information collected from...

NDA Submitted for Duvelisib for CLL and Follicular Lymphoma

A New Drug Application (NDA) was submitted for the oral phosphoinositide 3-kinase (PI3K) dual inhibitor duvelisib for the treatment of relapsed/refractory chronic lymphocytic leukemia...

Specialty Hospitals Benefit More From CMS Star Ratings

An analysis from Modern Healthcare found that the Centers for Medicare & Medicaid Services’ (CMS) star-ratings formula disproportionately benefits specialty hospitals, compared with major teaching...
Advertisement

Current Issue

October 2018, Volume 4, Issue 12

This issue features a look at the Right to Try debate, a breakdown of how epigenetics are used in hematology, and more.